Exploration of differences in tolerance of anthracycline-based chemotherapy between Caucasian and Asian breast cancer patients

Sydney Cancer Centre0 个研究点目标入组 120 人开始时间: 2010年1月15日最近更新: 2020年1月13日

适应症

试验速览

暂无简介。

•Asian or Caucasian patients.
•-Histologically confirmed breast cancer.
•-Women with non-metastatic breast cancer for whom adjuvant chemotherapy with AC or EC or FEC is appropriate
•-Age greater than or equal to 18.
•-Eastern Cooperative Oncology Group (ECOG)Performance Status of 0-2.
•-Ability to comply with the planned procedures and provide written evidence of informed consent.
•-Adequate haematology and biochemistry. (Haemoglobin>100 g/L, White blood cell count >4.0 x 109/L, neutrophil count > 1.5 × 109, platelets >100 x 109/L; Aspartate transaminase (AST), Alanine transaminase (ALT) and bilirubin < 1.5 x ULN (AST, ALT < 5 x upper limit of normal in case liver metastases); calculated creatinine clearance according to Corkroft formula > 60 ml/min.

•-Patients who require dose adjustment.
•-Clinical evidence of brain metastases.
•-Suspected or documented bone marrow involvement.
•-Significant intercurrent illness including active infection, inflammatory bowel disease or other uncontrolled autoimmune disease.
•-The requirement for ongoing systemic treatment with corticosteroids or other immunosuppressive therapy.
•-Patients who have had chemotherapy 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier
•-Ongoing major side effects from radiology.
•-Other active malignancy.
•-Known allergy to any of the investigational agents.

发起方

Sydney Cancer Centre